This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
News|Articles|June 27, 2022
Pierre Fabre and Lonza Enter Manufacturing Agreement
Author(s)Pharmaceutical Technology Editors
Lonza will produce drug product for Pierre Fabre’s monoclonal antibody W0180.
Advertisement
Lonza announced that it has entered into a manufacturing agreement with Pierre Fabre on June 15, 2022. Lonza will provide Pierre Fabre with drug product manufacturing services for clinical supply from its fill/finish facility in Stein, Switzerland.
According to a company press release, the collaboration is aimed at manufacturing W0180, a monoclonal antibody (mAb) that is currently being investigated as a single agent and in combination with pembrolizumab in various solid tumors. It targets the V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA), a negative checkpoint regulator of T-cell response that is expressed in the tumor microenvironment. The mAb is currently in a Phase I clinical trial.
"The W0180 will be manufactured in Lonza's GS Xceed Expression CHO [Chinese hamster ovary] System, also successfully used for the IGF1R [insulinlike growth factor1 receptor] and cMet antibodies discovered by Pierre Fabre," said Jean-Luc Lowinksi, CEO, Pierre Fabre Medical Care.
Source: Pierre Fabre
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement